ClinicalTrials.gg
RecruitingNCT04861558EFFIPECUpdated May 30, 2025

Efficacy of Hyperthermic Intraperitoneal Chemotherapy

A Phase 3 interventional study of 5Fluorouracil and Irinotecan in Colorectal Cancer and Peritoneal Metastases, sponsored by Uppsala University. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Uppsala University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Planned enrollment
36th of 132
213 · median 66
Started
2021
with 3 others
Phase 3
40 of 159
2 open now
Primary completion
2025-12
later than 4 of 18 live
Registered
144th of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 36th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2021, is one of 40 in phase 3, reaches primary completion later than 4 of the 18 other live ones, and was the 144th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

A dose titration study and a combined superiority registry-based open-label randomized control trial is planned to answer the trial objectives. The study will be registry-based to allow simpler and more comprehensive follow-up. Patients with colorectal cancer will be treated with cytoreductive surgery (CRS) together with either standard oxaliplatin HIPEC (the control for the efficacy study) or oxaliplatin/irinotecan HIPEC in combination with 5-FU 24-hour EPIC. The 5-FU will be administered postoperatively when the abdomen is completely sutured. The drug is divided equally into 2 injections of 200 ml each and injected through two abdominal drains that are clamped for 16 hours.

For dose escalation, the titration groups (á 3 or 6 patients) are followed for 30 days postoperatively after which the Data Monitoring Committee (DMC) will determine whether or not to increase the 5-FU dose for the following group of patients.

To study efficacy, randomization is performed intraoperatively. The patient is followed up postoperatively for a total of 3 years for the secondary endpoints which may be extended by the study committee to 5 years. Since the trial is registry based, the long-term follow-up does not require separate eCRF evaluations. These evaluations can be automatically retrieved from the registry - both recurrence data, quality of life, and morbidity data. Some specific eCRF evaluations will be integrated as a separate study part of the HIPEC registry, such as inclusion/exclusion criteria and adverse event reporting (including SUSAR reporting).

Read the detailed description

Not detailed description entered.

03

Conditions studied

  • Colorectal Cancer
  • Peritoneal Metastases
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written prior to any study specific procedures.
  2. Performance Status Score 0,1 or 2 alternatively 60-100
  3. Adequate kidney, liver, bone marrow function according to laboratory tests
  4. For females of , a negative pregnancy test must be documented
  5. ≥ 18 years old and ≤78 years old
  6. Colorectal cancer with peritoneal +/- liver metastases (maximum 3)
  7. Concomitant resectable pulmonary metastases are allowed
  8. All patients deemed eligible for CRS and HIPEC according to clinical routine management during a HIPEC multidisciplinary board at each respective hospital can be included.

Exclusion criteria

Exclusion criteria:

  1. Previous severe toxicity/allergic reactions to systemic chemotherapy agents oxaliplatin or irinotecan or 5-fluorouracil
  2. Unable to tolerate intensified HIPEC treatment due to comorbidity
  3. other than peritoneum or liver or lung
  4. Complex liver-perenchymal sparing surgery or hemihepatectomy procedures are to be excluded.
  5. Previous CRS or HIPEC
  6. Pregnant or lactating (nursing) women
  7. Active infections requiring antibiotics
  8. Active liver disease with positive serology for active , C, or known
  9. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to and up to 4 weeks after study treatment
  10. Incomplete cytoreduction defined as completeness of cytoreduction score 2-3
  11. Histopathology of other origin than colorectal cancer
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (estimated)

Study arms

  • Active comparator
    Standard HIPEC

    Injection of oxaliplatin 460 mg/m2 and an intraoperational IV of 5-fluorouracil 400 mg/m2, and calcium folinate 60 mg/m2.

    Drug: Oxaliplatin

  • Experimental
    Intensified HIPEC+EPIC

    Injection of irinotecan 360 mg/m2 and 5-fluorouracil 24-hr EPIC 250-850 mg/m2 in combination with Oxaliplatin 360 mg/m2 and an intraoperational IV of 5-fluorouracil bolus 400 mg/m2 with calcium folinate 60mg/m2. The EPIC treatment is given after the abdomen is completely sutured in the operating theater. The dose will be divided equally into 2 injections á 200ml each through two abdominal drains.

    Drug: 5Fluorouracil · Drug: Irinotecan · Drug: Oxaliplatin

Interventions

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection of 250-850 mg/m2.

    Also known as: Fluorouracil Accord, Fluorouracil Tevo

  • Injection of 360 mg/m2

    Also known as: Irinotecan Accord, Irinotecan Actavis, Irinotecan Fresenius Kabi

  • Injection of 460 mg/m2

    Also known as: Oxaliplatin Accord, Oxaliplatin Teva, Oxaliplatin Fresenius Kabi

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    To study the recurrence-free survival (RFS) of patients

    Time frame: 24 months after treatment

Secondary outcomes

  1. Overall survival

    Survival is followed through the HIPEC registry.

    Time frame: 5 years after treatment

  2. Recurrence-free survival

    Survival is followed through the HIPEC registry. The RECIST criteria are used to determine recurrence and site of first recurrence

    Time frame: 5 years after treatment

  3. Postoperative complication rate

    Morbidity is registered in the HIPEC registry within 30 days of treatment administration.

    Time frame: Within 30 days after treatment

  4. Patient evaluations of quality of life

    EORTC QLQ questionnaire filled out at baseline, 12 and 36 months after surgery using the established QoL database.

    Time frame: 3 years after treatment

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Completely anonymized IPD will be shared. All dates, HIPEC center treatment, referral city, and personal identification will be removed.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: To be shared at the time of phase 3 trial publication. Available for 10 years.

Access criteria: Access by request only from the corresponding author. Study protocol, SAP, ICF will be publicly available without request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2025, 55 months after the start.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's planned 55 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 27, 2021
StartActual
May 1, 2021
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2029
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04861558
Lead sponsor
Uppsala University
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
May 1, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2029 (estimated)
Last update
May 30, 2025

Study contacts

Peter Cashin, MD, PhD
Contact
peter.cashin@surgsci.uu.se
+46 (0)18 6174304
Lana Ghanipour, MD, PhD
Contact
lana.ghanipour@surgsci.uu.se
+46 (0)18 6110000
Peter Cashin, MD, PhD
principal investigator · Uppsala University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Irinotecan

Start the discussion